特发性膜性肾病合并静脉血栓栓塞的机制研究进展

betway必威登陆网址（betway.com ）学报››2023,Vol. 44››Issue (8): 603-607.DOI:10.3969/j.issn.2097-0005.2023.08.010

特发性膜性肾病合并静脉血栓栓塞的机制研究进展

李安壮(), 梁黎明, 许冬梅()

betway必威登陆网址第一附属医院肾脏病学科，山东济南 250014

收稿日期:2023-01-14出版日期:2023-08-25发布日期:2023-09-14
通讯作者:许冬梅
作者简介:李安壮，硕士研究生，研究方向：特发性膜性肾病， E-mail：laz155950@163.com。
基金资助:
国家自然科学基金面上项目(81970615)

Advances in the mechanism of idiopathic membranous nephropathy combined with venous thromboembolism

Anzhuang LI(), Liming LIANG, Dongmei XU()

Department of Nephrology，The First Affiliated Hospital of Shandong First Medical University，Jinan 250014，China

Received:2023-01-14Online:2023-08-25Published:2023-09-14
Contact:Dongmei XU

摘要/Abstract

摘要：

静脉血栓栓塞症（venous thromboembolism， VTE）是特发性膜性肾病（idiopathic membranous nephropathy， IMN）患者常见的并发症之一，是导致IMN患者死亡的重要因素。现有研究提示：高凝状态、血小板的异常激活、抗凝和凝血及纤溶系统失衡、内皮损伤和糖皮质激素的应用等因素是导致VTE发生的主要原因，炎症介质和免疫系统的调节对于VTE的发展也至关重要。目前关于IMN患者并发VTE机制的探究是广泛的，本文汇总近年国内外相关研究进展，对IMN合并VTE的发病机制进行综合阐述，为IMN患者的血栓预防及治疗提供理论支持。

关键词:特发性膜性肾病,静脉血栓栓塞,高凝状态

Abstract:

Venous thromboembolism （VTE） is one of the common complications in patients with idiopathic membranous nephropathy （IMN） and is an important factor in the death of patients with IMN. Existing studies suggest that factors such as hypercoagulable state， abnormal activation of platelets， anticoagulation and coagulation and fibrinolytic system imbalance， endothelial injury， and glucocorticoid use are the main causes of VTE， and inflammatory mediators and immune system regulation are also crucial for the development of VTE. At present， the mechanism of VTE complicated by IMN patients is extensive， and this article summarizes the relevant research progress at home and abroad in recent years， and comprehensively elaborates the pathogenesis of IMN combined with VTE so as to provide theoretical support for thromboprevention and treatment in IMN patients.

Key words:idiopathic membranous nephropathy,venous thromboembolism,hypercoagulable state

李安壮, 梁黎明, 许冬梅. 特发性膜性肾病合并静脉血栓栓塞的机制研究进展[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(8): 603-607.

Anzhuang LI, Liming LIANG, Dongmei XU. Advances in the mechanism of idiopathic membranous nephropathy combined with venous thromboembolism[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(8): 603-607.

参考文献19

1	Li Y， Yu X， Zhang W， et al. Epidemiological characteristics and pathological changes of primary glomerular diseases［J］. PLoS One， 2022， 17（8）： e0272237.
2	Nieto-Gañán I， Iturrieta-Zuazo I， Rita C， et al. Revisiting immunological and clinical aspects of membranous nephropathy［J］. Clin Immunol， 2022， 237： 108976.
3	Zou H， Li Y， Xu G. Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy［J］. BMC Nephrol， 2019， 20（1）： 442.
4	Zou PM， Li H， Cai JF， et al. A cohort study of incidences and risk factors for thromboembolic events in patients with idiopathic membranous nephropathy［J］. Chin Med Sci J， 2018， 33（2）： 91.
5	Waller AP， Troost JP， Parikh SV， et al. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy［J］. Thromb Res， 2021， 201： 50.
6	Kerlin BA， Ayoob R， Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease［J］. Clin J Am Soc Nephrol， 2012， 7（3）： 513.
7	Loscalzo J. Venous thrombosis in the nephrotic syndrome［J］. N Engl J Med， 2013， 368（10）： 956.
8	May JE， Wolberg AS， Lim MY. Disorders of fibrinogen and fibrinolysis［J］. Hematol Oncol Clin North Am， 2021， 35（6）： 1197.
9	Arisz RA， De Vries JJ， Schols SEM， et al. Interaction of von Willebrand factor with blood cells in flow models： a systematic review［J］. Blood Adv， 2022， 6（13）： 3979.
10	Parker ET， Haberichter SL， Lollar P. Subunit flexibility of multimeric von Willebrand factor/factor Ⅷ complexes［J］. ACS Omega， 2022， 7（35）： 31183.
11	Lagrange J， Lecompte T， Knopp T， et al. Alpha-2-macroglobulin in hemostasis and thrombosis： an underestimated old double-edged sword［J］. J Thromb Haemost， 2022， 20（4）： 806.
12	Martos L， Ramón LA， Oto J， et al. α2-macroglobulin is a significantin vivoinhibitor of activated protein C and low APC： α2M levels are associated with venous thromboembolism［J］. Thromb Haemost， 2018， 118（4）： 630.
13	Singhal R， Brimble KS. Thromboembolic complications in the nephrotic syndrome： pathophysiology and clinical management［J］. Thromb Res， 2006， 118（3）： 397.
14	Wu T， Tang LV， Hu Y. Venous thromboembolism in kidney diseases and genetic predisposition［J］. Kidney Dis （Basel）， 2022， 8（3）： 181.
15	Angeletti A， Migliorini P， Bruschi M， et al. Anti-alpha enolase multi-antibody specificity in human diseases. Clinical significance and molecular mechanisms［J］. Autoimmun Rev， 2021， 20（12）： 102977.
16	López-Alemany R， Longstaff C， Hawley S， et al. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against α-enolase［J］. Am J Hematol， 2003， 72（4）： 234.
17	Ishikawa T， Nakajima Y， Omae T， et al. Comprehensive coagulation and fibrinolytic potential in the acute phase of pediatric patients with idiopathic nephrotic syndrome evaluated by whole blood-based rotational thromboelastometry［J］. Pediatr Nephrol， 2022， 37（7）： 1605.
18	Inamdar N， Tomer S， Kalmath S， et al. Reversal of endothelial dysfunction post-immunosuppressive therapy in adult-onset podocytopathy and primary membranous nephropathy［J］. Atherosclerosis， 2020， 295： 38.
19	Roca N， Jatem E， Martín ML， et al. Relationship between soluble urokinase-type plasminogen activator receptor and serum biomarkers of endothelial activation in patients with idiopathic nephrotic syndrome［J］. Clin Kidney J， 2021， 14（2）： 543.